Semaglutide Weight Loss Therapy in Miami, FL
Clinically proven GLP-1 receptor agonist therapy supervised by the medical team at Rewind Anti-Aging of Miami. Patients in the landmark STEP trials lost an average of 14.9% of their body weight.
Call (305) 922-9622 Request a ConsultationWhat Is Semaglutide?
Semaglutide is an injectable prescription medication that belongs to a class of drugs known as GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists). It was originally developed and FDA-approved for the treatment of Type 2 diabetes, where it helps regulate blood sugar by stimulating insulin production when glucose levels are elevated. However, during clinical trials for diabetes, researchers observed a remarkable secondary benefit: significant, sustained weight loss.
That discovery led to a new chapter for semaglutide. In June 2021, the FDA approved a higher-dose formulation specifically for chronic weight management in adults with obesity or overweight conditions accompanied by at least one weight-related comorbidity such as hypertension, Type 2 diabetes, or dyslipidemia. Today, semaglutide stands as one of the most thoroughly studied and effective pharmaceutical tools available for medically supervised weight loss.
At Rewind Anti-Aging of Miami, we prescribe semaglutide as part of a comprehensive, physician-supervised weight-loss program. Our approach combines the medication with nutritional guidance, lifestyle coaching, and ongoing monitoring so that every patient receives a treatment plan built around their unique physiology and goals.
How Semaglutide Works: The Science Behind GLP-1 Therapy
Understanding how semaglutide produces weight loss requires a look at the hormone it mimics. GLP-1 is a naturally occurring incretin hormone released by the small intestine after you eat. It plays several roles in metabolic regulation, and semaglutide amplifies those roles in three key ways:
1. Appetite Suppression via Central Nervous System Signaling
Semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamus, the region of the brain responsible for hunger and satiety signaling. By activating these receptors, the medication reduces the neurological drive to eat, helping patients feel satisfied with smaller portions and experience fewer cravings throughout the day. This is not willpower—it is a biochemical shift in how your brain perceives hunger.
2. Delayed Gastric Emptying
Semaglutide slows the rate at which food leaves the stomach and enters the small intestine. This prolonged gastric transit means you feel full longer after a meal. The slower digestion also helps blunt post-meal blood sugar spikes, which reduces the insulin surges that can trigger fat storage and subsequent energy crashes.
3. Improved Insulin Sensitivity and Glucose Metabolism
By enhancing the body's insulin response and suppressing excess glucagon secretion, semaglutide improves overall glucose metabolism. Better insulin sensitivity means your cells are more efficient at using glucose for energy rather than storing it as fat. This metabolic improvement benefits patients regardless of whether they have a diabetes diagnosis.
Together, these three mechanisms create a powerful, multi-pathway approach to weight reduction that addresses both the behavioral and metabolic drivers of obesity.
Clinical Evidence: What the Research Says
Semaglutide's efficacy for weight loss is supported by one of the most robust clinical trial programs in obesity medicine history: the STEP (Semaglutide Treatment Effect in People with Obesity) trials.
STEP 1 Trial Results
Published in the New England Journal of Medicine in February 2021, the STEP 1 trial enrolled 1,961 adults with obesity or overweight status plus at least one weight-related comorbidity. Participants received once-weekly subcutaneous semaglutide at a dose of 2.4 mg alongside lifestyle intervention. The results were striking:
- Average body weight loss of 14.9% over 68 weeks in the semaglutide group, compared to just 2.4% in the placebo group
- One-third of participants lost 20% or more of their body weight
- Significant improvements in cardiometabolic risk factors including waist circumference, blood pressure, and lipid levels
- Meaningful reductions in C-reactive protein, a marker of systemic inflammation
Additional STEP Trials
The broader STEP program included multiple trials (STEP 2 through STEP 5) that confirmed these findings across diverse populations, including patients with Type 2 diabetes, varying ethnicities, and different baseline BMI ranges. STEP 4 demonstrated that discontinuing semaglutide led to partial weight regain, underscoring the importance of a sustained treatment approach—something we prioritize at Rewind Anti-Aging of Miami through our long-term patient monitoring protocols.
The SELECT trial, published in 2023, further demonstrated a 20% reduction in major adverse cardiovascular events among overweight or obese adults with established cardiovascular disease who received semaglutide, adding a cardioprotective dimension to the medication's benefit profile.
Semaglutide vs. Ozempic vs. Wegovy: Understanding the Brand Names
One of the most common sources of confusion for patients researching GLP-1 therapy is the relationship between semaglutide, Ozempic, and Wegovy. Here is a clear breakdown:
Semaglutide
This is the active pharmaceutical ingredient—the molecule itself. It is the generic name for the drug compound developed by Novo Nordisk. When we discuss semaglutide therapy at our clinic, we are referring to this active compound.
Ozempic
A brand-name injectable semaglutide product FDA-approved for Type 2 diabetes. It is available in doses up to 2.0 mg per week. While physicians may prescribe Ozempic off-label for weight loss, its primary indication and insurance coverage are for diabetes management.
Wegovy
A brand-name injectable semaglutide product FDA-approved specifically for chronic weight management. It reaches a maximum dose of 2.4 mg per week—higher than Ozempic—and was the formulation used in the STEP clinical trials that demonstrated the 14.9% average weight loss.
There is also Rybelsus, an oral semaglutide tablet approved for Type 2 diabetes, though it is not typically used for weight loss due to lower bioavailability compared to the injectable form.
At Rewind Anti-Aging of Miami, we work with compounded semaglutide formulations prescribed specifically for weight management. During your consultation, our providers will explain which option best fits your medical history, insurance situation, and weight-loss goals.
Dosing and Titration Schedule
Semaglutide is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The dosing follows a gradual titration schedule designed to minimize side effects and allow your body to adjust to the medication:
| Phase | Weeks | Weekly Dose | Purpose |
|---|---|---|---|
| Month 1 | Weeks 1–4 | 0.25 mg | Initial introduction; body acclimates to GLP-1 activity |
| Month 2 | Weeks 5–8 | 0.5 mg | First therapeutic increase; appetite changes become noticeable |
| Month 3 | Weeks 9–12 | 1.0 mg | Continued escalation; significant appetite suppression for most patients |
| Month 4 | Weeks 13–16 | 1.7 mg | Approaching target dose; weight loss typically accelerates |
| Month 5 | Weeks 17–20+ | 2.4 mg | Full maintenance dose; maximum therapeutic effect achieved |
This 16-to-20-week escalation period is critical. Jumping to higher doses too quickly is the most common cause of gastrointestinal discomfort. Our medical team at Rewind Anti-Aging of Miami monitors your progress at every step and may adjust the timeline based on your tolerance and response. Some patients achieve their goals at lower doses and never need to reach the full 2.4 mg.
What to Expect Week by Week on Semaglutide
Every patient's experience is unique, but the following timeline represents what most patients at our Miami clinic report during semaglutide therapy:
Weeks 1–2: Early Adjustment
During the initial 0.25 mg phase, most patients notice a subtle reduction in appetite and food noise—that persistent mental chatter about what to eat next. Hunger between meals may decrease, and you might find yourself naturally reaching for smaller portions. Some patients experience mild nausea that typically resolves within a few days. Weight loss during this phase is usually modest, ranging from one to three pounds.
Weeks 3–4: Building Momentum
Still at the introductory dose, appetite suppression becomes more consistent. Many patients report losing interest in snacking and finding it easier to skip desserts or late-night eating. Cumulative weight loss of three to five pounds is common by the end of the first month.
Month 2 (Weeks 5–8): Noticeable Changes
After the first dose increase to 0.5 mg, appetite reduction is more pronounced. Patients frequently describe feeling full after eating half their usual portion. Weight loss of five to ten pounds from baseline is typical. Energy levels often improve as the body begins mobilizing stored fat for fuel. Mild GI symptoms may briefly return after the dose increase but tend to subside within a week.
Month 3 (Weeks 9–12): Accelerating Results
At 1.0 mg, the weight-loss trajectory steepens for most patients. Clothes begin fitting differently, and friends or colleagues may start commenting on visible changes. Total weight loss of 8 to 15 pounds from baseline is common. Blood sugar and cholesterol panels often show measurable improvement at this stage.
Months 4–5 (Weeks 13–20): Reaching Full Dose
As patients titrate through 1.7 mg and reach the 2.4 mg maintenance dose, weight loss continues at a steady pace. By week 20, many patients have lost 10 to 20% of their starting body weight. The relationship with food often shifts fundamentally—patients describe eating to fuel their body rather than eating out of habit or emotion.
Months 6–12+: Long-Term Maintenance
Weight loss continues gradually and typically plateaus around months 12 to 16. Our team works with you on nutrition optimization and, when appropriate, exercise programming to lock in your results and prepare for eventual treatment completion.
Side Effects and Safety Information
Like all prescription medications, semaglutide carries potential side effects. Transparency about risks is a core part of the informed-consent process at Rewind Anti-Aging of Miami.
Common Side Effects (Gastrointestinal)
The most frequently reported side effects are GI-related and tend to be mild to moderate in severity:
- Nausea — the most common side effect, reported by approximately 44% of patients in clinical trials; typically worst during the first few weeks and after dose increases
- Diarrhea — reported by roughly 30% of participants
- Constipation — affects approximately 24% of patients
- Vomiting — occurs in about 24% of patients, usually transient
- Abdominal discomfort — mild cramping or bloating, particularly after meals
These effects are dose-dependent, which is precisely why the gradual titration schedule exists. Most patients find that symptoms resolve or become manageable within one to two weeks of each dose adjustment.
Less Common Side Effects
- Headache and fatigue during the early weeks of treatment
- Dizziness, particularly in patients who reduce caloric intake rapidly
- Injection site reactions such as mild redness or itching
Rare but Serious Risks
- Pancreatitis: Patients should report severe, persistent abdominal pain immediately
- Gallbladder disease: Rapid weight loss of any kind can increase gallstone risk
- Hypoglycemia: Uncommon when semaglutide is used alone but possible when combined with insulin or sulfonylureas
Thyroid C-Cell Tumor Warning (Boxed Warning)
Semaglutide carries an FDA boxed warning based on animal studies in which GLP-1 receptor agonists caused thyroid C-cell tumors in rodents. It remains unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. As a precaution, semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Our medical team screens for these conditions before prescribing.
Who Is a Candidate for Semaglutide Therapy?
Semaglutide for weight management is appropriate for adults who meet specific clinical criteria. At Rewind Anti-Aging of Miami, we evaluate every patient individually, but general candidacy guidelines include:
BMI-Based Criteria
- BMI of 30 or greater (classified as obesity) — qualifies for semaglutide regardless of other conditions
- BMI of 27 or greater (classified as overweight) — qualifies when accompanied by at least one weight-related comorbidity such as hypertension, Type 2 diabetes, dyslipidemia, or obstructive sleep apnea
Ideal Candidates Also Include Those Who:
- Have struggled with yo-yo dieting and repeated weight regain
- Have been unable to achieve sustainable results through diet and exercise alone
- Want a medically supervised, evidence-based approach to weight loss
- Are motivated to combine medication with healthy lifestyle changes
- Are seeking cardiovascular risk reduction alongside weight management
Who Should Not Take Semaglutide
- Individuals with a personal or family history of medullary thyroid carcinoma (MTC)
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Women who are pregnant, planning to become pregnant, or breastfeeding
- Patients with a history of severe pancreatitis
- Individuals with known hypersensitivity to semaglutide or any product components
Frequently Asked Questions About Semaglutide
How much weight can I lose on semaglutide?
Clinical trial data from the STEP program showed participants lost an average of 14.9% of their body weight over 68 weeks. Individual results vary based on starting weight, adherence to the dosing schedule, diet, and physical activity. Many patients at Rewind Anti-Aging of Miami begin noticing meaningful weight loss within the first four to six weeks of treatment.
Is semaglutide the same as Ozempic or Wegovy?
Semaglutide is the active pharmaceutical ingredient found in both Ozempic and Wegovy. Ozempic is FDA-approved specifically for Type 2 diabetes management, while Wegovy is approved for chronic weight management. At our Miami clinic, we prescribe compounded semaglutide tailored to your weight-loss goals and medical history.
How long do I need to take semaglutide?
Most patients follow a treatment course of six months to one year, though the optimal duration depends on your individual goals and response to therapy. Our providers at Rewind Anti-Aging of Miami create a personalized timeline during your initial consultation and adjust it as you progress through your weight-loss journey.
What are the most common side effects of semaglutide?
The most frequently reported side effects are gastrointestinal in nature, including nausea, diarrhea, constipation, and occasional vomiting. These symptoms are typically mild, occur early in treatment or after dose increases, and tend to diminish as your body adjusts. Our gradual titration protocol is specifically designed to minimize these effects.
Do I need to follow a special diet while taking semaglutide?
While no single diet is required, we strongly recommend a balanced, nutrient-dense eating plan that emphasizes lean proteins, vegetables, and whole grains. Semaglutide reduces appetite naturally, which makes it easier to maintain a caloric deficit. Our team provides dietary guidance as part of your comprehensive treatment plan.
Will I regain weight after stopping semaglutide?
Research indicates that some weight regain can occur after discontinuation if lifestyle habits are not maintained. That is why our approach at Rewind Anti-Aging of Miami pairs semaglutide therapy with nutrition counseling and sustainable lifestyle modifications to help you maintain your results long after treatment concludes.
Can I take semaglutide if I do not have diabetes?
Yes. While semaglutide was originally developed for Type 2 diabetes, it is FDA-approved under the brand name Wegovy for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition. You do not need a diabetes diagnosis to qualify.
How do I get started with semaglutide therapy at Rewind Anti-Aging of Miami?
Getting started is straightforward. Call us at (305) 922-9622 or request a consultation through our website. During your initial visit, our medical team will review your health history, check your BMI and lab work, and determine whether semaglutide is the right fit for your weight-loss goals.
Start Your Semaglutide Weight Loss Journey in Miami
Semaglutide therapy at Rewind Anti-Aging of Miami is more than a prescription—it is a physician-guided program designed to help you lose weight safely, improve your metabolic health, and build habits that last. Whether you have 30 pounds to lose or 100, our medical team will create a plan tailored to your body and your goals.
Call us today at (305) 922-9622 or request a consultation online to find out if semaglutide is right for you.